高级检索
当前位置: 首页 > 详情页

Melatonin protects against NMDA-induced retinal ganglion cell injury by regulating the microglia-TNF?-RGC p38 MAPK pathway

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Cent South Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha, Peoples R China [2]Hunan Clin Res Ctr Ophthalm Dis, Changsha, Peoples R China [3]Chinese Peoples Liberat Army Med Sch, Beijing, Peoples R China [4]Hunan Univ Chinese Med, Changsha, Hunan, Peoples R China [5]Hunan Univ Chinese Med, Affiliated Hosp 1, Changsha, Hunan, Peoples R China [6]139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China
出处:
ISSN:

关键词: MOUSE MODEL INHIBITION KINASE NEUROTOXICITY ACTIVATION INFLIXIMAB STRESS ALPHA DEATH

摘要:
Glaucoma, one of the most common ocular neurodegenerative diseases worldwide, is characterized by retinal ganglion cell (RGC) loss. There is a large body of literature that describes the neuroprotective role of melatonin against neurodegenerative diseases by regulating neuroinflammation, although the exact mechanism through which melatonin acts on RGC is still uncertain. This study assessed the protective effects of melatonin using a NMDA-induced RGC injury model, and studied the possible mechanisms involved in this process. Melatonin promoted RGC survival, improved retinal function, and inhibited the apoptosis and necrosis of retinal cells. To understand the mechanism of the neuroprotective effects of melatonin on RGC, microglia and inflammation -related pathways were assessed after melatonin administration and microglia ablation. Melatonin promoted RGC survival by suppressing microglia-derived proinflammatory cytokines, in particular TNF alpha, which in turn inhibited the activation of p38 MAPK pathway. Inhibiting TNF alpha or manipulating p38 MAPK pathway protected damaged RGC. Our results suggest that melatonin protects against NMDA-induced RGC injury by inhibiting the microglial TNF alpha-RGC p38 MAPK pathway. It should be considered a candidate neuroprotective therapy against retinal neurodegenerative diseases.

基金:

基金编号: CX20210115 2021zzts0358 82070967 81700837 81770930

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 2 区 医学
小类 | 2 区 免疫学 2 区 药学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 免疫学 2 区 药学
JCR分区:
出版当年[2021]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Cent South Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha, Peoples R China [2]Hunan Clin Res Ctr Ophthalm Dis, Changsha, Peoples R China
通讯作者:
通讯机构: [*1]139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China [6]139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)